Posted by Michael Wonder on 02 Feb 2024
Tyra Biosciences receives FDA rare paediatric disease designation for TYRA-300 for the treatment of achondroplasia
1 February 2024 - Tyra Biosciences today announced that the US FDA has granted rare paediatric disease designation to TYRA-300, an oral FGFR3 selective inhibitor, for the treatment of achondroplasia.
TYRA is planning to submit an Investigational new drug application to the FDA in the second half of 2024 for the initiation of a randomised Phase 2 clinical trial evaluating multiple dose cohorts of TYRA-300 for children with achondroplasia.
